High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Im, Eui | - |
dc.contributor.author | Cho, Yun-Hyeong | - |
dc.contributor.author | Suh, Yongsung | - |
dc.contributor.author | Cho, Deok-Kyu | - |
dc.contributor.author | Her, Ae-Young | - |
dc.contributor.author | Kim, Yong Hoon | - |
dc.contributor.author | Lee, Kyounghoon | - |
dc.contributor.author | Kang, Woong Chol | - |
dc.contributor.author | Yun, Kyeong Ho | - |
dc.contributor.author | Yoo, Sang-Yong | - |
dc.contributor.author | Cheong, Sang-Sig | - |
dc.contributor.author | Shin, Dong-Ho | - |
dc.contributor.author | Ahn, Chul-Min | - |
dc.contributor.author | Kim, Jung-Sun | - |
dc.contributor.author | Kim, Byeong-Keuk | - |
dc.contributor.author | Ko, Young-Guk | - |
dc.contributor.author | Choi, Donghoon | - |
dc.contributor.author | Jang, Yangsoo | - |
dc.contributor.author | Hong, Myeong-Ki | - |
dc.date.available | 2020-02-27T10:42:10Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-06 | - |
dc.identifier.issn | 0300-8932 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3726 | - |
dc.description.abstract | Introduction and objectives: Current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (DES)-treated patients. However, high-intensity statin treatment is frequently underused in clinical practice after stabilization of DES-treated patients. Currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. We investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after DES implantation. Methods: Clinically stable patients who underwent DES implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40 mg atorvastatin, n = 1000) or low-intensity (20 mg pravastatin, n = 1000) statin treatment. The primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events). Results: The primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving highintensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (HR, 0.58; 95%Cl, 0.36-0.92; P = .018). This difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, P = .025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, P = .033) in the high-intensity statin treatment group. Conclusions: Among clinically stable DES-treated patients on aspirin monotherapy, high-intensity statin treatment significantly reduced late adverse events compared with low-intensity statin treatment. (C) 2017 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved. | - |
dc.language | 스페인어 | - |
dc.language.iso | es | - |
dc.publisher | EDICIONES DOYMA S A | - |
dc.relation.isPartOf | REVISTA ESPANOLA DE CARDIOLOGIA | - |
dc.subject | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject | DUAL ANTIPLATELET THERAPY | - |
dc.subject | LIPID-LOWERING THERAPY | - |
dc.subject | ATORVASTATIN | - |
dc.subject | DISEASE | - |
dc.subject | PRAVASTATIN | - |
dc.subject | THROMBOSIS | - |
dc.subject | COVERAGE | - |
dc.subject | OUTCOMES | - |
dc.subject | TRIALS | - |
dc.title | High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000434896600005 | - |
dc.identifier.doi | 10.1016/j.rec.2017.06.008 | - |
dc.identifier.bibliographicCitation | REVISTA ESPANOLA DE CARDIOLOGIA, v.71, no.6, pp.423 - 431 | - |
dc.identifier.scopusid | 2-s2.0-85031750780 | - |
dc.citation.endPage | 431 | - |
dc.citation.startPage | 423 | - |
dc.citation.title | REVISTA ESPANOLA DE CARDIOLOGIA | - |
dc.citation.volume | 71 | - |
dc.citation.number | 6 | - |
dc.contributor.affiliatedAuthor | Lee, Kyounghoon | - |
dc.contributor.affiliatedAuthor | Kang, Woong Chol | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Coronary artery disease | - |
dc.subject.keywordAuthor | Drug-eluting stent | - |
dc.subject.keywordAuthor | Statin | - |
dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject.keywordPlus | DUAL ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | LIPID-LOWERING THERAPY | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | PRAVASTATIN | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordPlus | COVERAGE | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | TRIALS | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.